PerClot, a passive, absorbable hemostatic powder, received FDA approval in May. Artivion developed the powder and transferred full ownership to Baxter as part of a sale agreement struck in July 2021.
Artivion designed PerClot to control mild bleeding in specific surgical procedures. It comes ready to use for patients with intact coagulation. The powder’s granules have a molecular structure that rapidly absorbs water to form a gelled adhesive matrix. This provides a mechanical barrier against further bleeding. It also results in the accumulation of platelets, red blood cells and coagulation proteins.
“PerClot is a strong complement to Baxter’s leading hemostat por…